HOME >> BIOLOGY >> NEWS
Stronger therapy better for AML with normal genetics

COLUMBUS, Ohio New research is helping select which therapies improve the chances of remission in the largest category of people affected by acute myeloid leukemia (AML) those whose cancer cells have normal-looking chromosomes.

The findings suggest that people receiving more intense therapies are more likely to enter remission and to remain there longer than those receiving lower-dose therapies.

The study was published online Nov. 8 by the Journal of Clinical Oncology.

The Cancer and Leukemia Group B (CALGB) study was initiated by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSU CCC-James). It is part of a larger CALGB cytogenetic trial chaired by Clara D. Bloomfield, professor of internal medicine and the William G. Pace III Professor in Cancer Research, OSU Cancer Scholar and senior adviser to the OSU cancer program.

Unexpectedly, the current study also found that patients who had an enlarged spleen at the time of their initial treatment were less likely to enter remission. AML patients are in remission when leukemic cells are not microscopically detectable among their bone-marrow cells.

"These preliminary findings raise the question of whether additional treatment directed specifically to the spleen might improve remission rates," says first author Sherif S. Farag, assistant professor of internal medicine and a medical oncologist with the OSU CCC-James. "At this point, this is just a hypothesis that needs to be tested, but it may be that the spleen is a sanctuary site for leukemic cells and needs separate treatment."

A diagnosis of AML routinely includes studying patients' leukemic cells for chromosome damage, a process known as cytogenetic analysis. The information helps determine the best therapy and a patient's chance of remission and cure. But 40 percent of AML patients have leukemic cells wit
'"/>

Contact: Darrell E. Ward
Ward-15@medctr.osu.edu
614-293-3737
Ohio State University
29-Nov-2004


Page: 1 2 3

Related biology news :

1. Stronger evidence found linking Epstein-Barr virus and risk of multiple sclerosis
2. Testosterone replacement therapy: How safe for aging men?
3. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
4. Aggressive therapy best for certain AML patients
5. Under magnetic force, nanoparticles may deliver gene therapy
6. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Stem cell therapy rescues motor neurons in ALS model
8. Study identifies new gene therapy tools for inherited blindness
9. Breast cancer and hormone therapy -- A looking-glass mirror?
10. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
11. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
Breaking Biology Technology:
Cached News: